Add Yahoo as a preferred source to see more of our stories on Google. Eli Lilly will speak with regulators about the Phase III data. Image credit: luchschenF / Shutterstock.com (luchschenF / ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant therapy versus placebo. The study met its ...

The global oncology market is projected to nearly triple from $279.98 billion in 2026 to an estimated $748.17 billion by 2035 ...

Some six years after the FDA approved Eli Lilly’s Retevmo to treat lung a | Six years after the FDA approved Eli Lilly’s Retevmo to treat lung and thyroid cancers with a rare biomarker, the ...

Background The epidemiology and long-term healthcare utilisation associated with chronic kidney disease (CKD) among those ...

LIBRETTO-432 shows statistically significant event-free survival benefit in RET fusion-positive NSCLC after initial therapy.

Eli Lilly and Co. (NYSE:LLY) on Monday shared positive topline results from the Phase 3 LIBRETTO-432 clinical trial for ...

Traditional approval of encorafenib plus cetuximab and fluorouracil-based chemotherapy for patients with BRAF-mutated ...

SGLT2 inhibitors showed significantly improved mortality benefits compared with DPP-4 inhibitors in patients with diabetic kidney disease (DKD) in a large target trial emulation study that adds ...

BeOne Medicines Q4 earnings and revenue beat the Street's expectations; the outlook missed by a small margin. Read why I have ...